

## Taltz® Coverage Determination Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		Office Contact:
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>		
Medication Name: Select one of the following: <input type="checkbox"/> Request is for <b>GENERIC</b> <input type="checkbox"/> Request is for <b>BRAND</b> (unable to take the generic)		Strength:
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>		Dosage Form:
Directions for Use:		

Clinical Information <small>(required)</small>
<b>Select the Type of Coverage Determination Requested:</b> <input type="checkbox"/> <b>Prior Authorization</b> - Request is for a drug that requires prior authorization under the plan.
<b>Select the diagnosis below:</b> <input type="checkbox"/> Plaque psoriasis <input type="checkbox"/> Psoriatic arthritis <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____
<b>Prescriber's Specialty:</b> Is the requested medication prescribed by a rheumatologist or dermatologist? <input type="checkbox"/> <b>Yes</b> <input type="checkbox"/> <b>No</b>
<b>Clinical Information:</b> Is there documentation that the patient had an inadequate response or inability to tolerate both adalimumab (Humira) and etanercept (Enbrel)? <input type="checkbox"/> <b>Yes</b> <input type="checkbox"/> <b>No</b> If "no" to the above question, is there documentation demonstrating that a trial of both adalimumab (Humira) and etanercept (Enbrel) may be inappropriate? <input type="checkbox"/> <b>Yes</b> <input type="checkbox"/> <b>No</b> Is there documentation that the patient has been evaluated for active or latent Tuberculosis (TB)? <input type="checkbox"/> <b>Yes</b> <input type="checkbox"/> <b>No</b> Is the patient receiving concurrent therapy with biologic DMARDs or other tumor necrosis factor antagonists? <input type="checkbox"/> <b>Yes</b> <input type="checkbox"/> <b>No</b> For new starts only: Has at least 2 weeks passed since administration of Herpes Zoster vaccine prior to the start of therapy? <input type="checkbox"/> <b>Yes</b> <input type="checkbox"/> <b>No</b>

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---



---

Please note: This request may be denied unless all required information is received.